Mesothelin and osteopontin

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 557-

  Hillerdal, Gunnar ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; OSTEOPONTIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; LETTER; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; MESOTHELIOMA; METABOLISM; NOTE; PLEURA TUMOR;

GPI-LINKED PROTEINS; HUMANS; MESOTHELIOMA; OSTEOPONTIN; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882699038     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00052213     Document Type: Letter

References (3)

1. Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 2013; 41: 706-715.
2. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-772.
3. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63.